propyl gallate has been researched along with Chronic Disease in 1 studies
Propyl Gallate: Antioxidant for foods, fats, oils, ethers, emulsions, waxes, and transformer oils.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
Excerpt | Relevance | Reference |
---|---|---|
" A combination of sodium chenodeoxycholate and propyl gallate was used to enhance bioavailability of MEDI7219 at the site of maximal gastrointestinal absorption, targeted by enteric-coated tablets." | 1.62 | Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. ( Balic, K; Grimsby, J; Huang, Y; Konkar, A; Liang, L; Naylor, J; Patel, C; Pechenov, S; Revell, J; Rosenbaum, AI; Subramony, JA; Tseng, L; Tyagi, P; Will, S, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Pechenov, S | 1 |
Revell, J | 1 |
Will, S | 1 |
Naylor, J | 1 |
Tyagi, P | 1 |
Patel, C | 1 |
Liang, L | 1 |
Tseng, L | 1 |
Huang, Y | 1 |
Rosenbaum, AI | 1 |
Balic, K | 1 |
Konkar, A | 1 |
Grimsby, J | 1 |
Subramony, JA | 1 |
1 other study available for propyl gallate and Chronic Disease
Article | Year |
---|---|
Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.
Topics: Administration, Oral; Animals; Caco-2 Cells; Chemistry, Pharmaceutical; Chenodeoxycholic Acid; CHO C | 2021 |